Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (1607)	11/5/1998 11:02:00 PM
From: Steve Harmon	Respond to of 2742

I agree with ANYTHING that will increase shareholder value. Cistron has $13 million in cash and cash receivables. No burn. No debt. 2 freakin investment bankers. 1 PR firm. A major drug partner Several lawyers I dare anyone on the SI biotech boards to name any small or micro-cap biotech company that has the above and is still trading at LESS than 1/2 cash. Again too bad Cistron shareholders did not receive IMNX stock instead of cash. IMNX has multiplied 6x since the settlement 2 years ago. Cistron stock has remained in the trash heap.

To: Dr. John M. de Castro who wrote (1607)	11/5/1998 11:20:00 PM
From: John Metcalf	Read Replies (1) \| Respond to of 2742

First, Peter IS crazy, and he knows it, because he is a knowledgable and experienced biotech investor looking at Cistron-:) Albeit as a loony savant, he sees a value, and has come to this wayward thread to share his confession of goofiness. High five! With John de Castro, I agree that a small cap listing would help the stock. The spread as a penny-stock discourages most investors (see above "Peter IS crazy"). With a 1:20 reverse split, CIST would trade at $5-6-7 or so, and the spread would not be so formidable.

To: Dr. John M. de Castro who wrote (1607)	11/5/1998 11:31:00 PM
From: Steve Harmon	Read Replies (1) \| Respond to of 2742

John de C, I would agree with you on the reverse split if Cistron were a earnings driven story. It did wonders for Medicis Pharm. a few years back. But of course Cistron is not a earnings story. Access to capital markets? Cistron has 2 investment bankers. Money is precious at Cistron? The 2 officers at Cistron have been paid almost a million dollars in 2 years...just paid out a $100,000 bonus. The excuse that Cistron had about protecting and conserving its most valuable resource CASH has been blown out of the water! Steve